DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • France
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
ERF logo

Eurofins Scientific SE Stock Price

ENXTPA:ERF Community·€13.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 36 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

ERF Share Price Performance

€76.44
13.76 (21.95%)
​
€72.53
Fair Value
€76.44
13.76 (21.95%)
5.4% overvalued intrinsic discount
€72.53
Fair Value
Price €76.44
AnalystConsensusTarget €72.53
AnalystHighTarget €86.00
AnalystLowTarget €58.00
Tue, 4 Aug 26
Fair Value€72.53
Share Pricen/a

ERF Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value €72.53 5.4% overvalued intrinsic discount

Digitalization And Automation Will Unlock Future Diagnostics Potential

0users have liked this narrative
0users have commented on this narrative
21users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value €86 11.1% undervalued intrinsic discount

Digital Investments And Rising Safety Mandates Will Expand Advanced Diagnostics

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value €58 31.8% overvalued intrinsic discount

Automation And Regulatory Hurdles Will Erode Traditional Lab Margins

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
ERF logo
Eurofins Scientific
5.4% overvalued intrinsic discount

Digitalization And Automation Will Unlock Future Diagnostics Potential

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 4 Aug
Read Narrative
ERF logo
Eurofins Scientific
31.8% overvalued intrinsic discount

Automation And Regulatory Hurdles Will Erode Traditional Lab Margins

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 21 Jul
Read Narrative
ERF logo
Eurofins Scientific
11.1% undervalued intrinsic discount

Digital Investments And Rising Safety Mandates Will Expand Advanced Diagnostics

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 29 May
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
ERF logo

ERF: Acquisition Plans And Buybacks Will Support Balanced Long Term Outlook

Fair Value: €72.53 5.4% overvalued intrinsic discount
21 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
ERF logo

ERF: Acquisition Plans And Hantavirus Testing Will Pressure Margins And Future P/E

Fair Value: €58 31.8% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
ERF logo

ERF: Expanded Hantavirus Testing Network Will Support Re Rating Potential

Fair Value: €86 11.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with proven track record.

1 Risk
4 Rewards
View Full Analysis

Eurofins Scientific SE Key Details

€7.4b

Revenue

€5.7b

Cost of Revenue

€1.7b

Gross Profit

€1.2b

Other Expenses

€469.9m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
2.71
23.13%
6.36%
87.3%
View Full Analysis

About ERF

Founded
1987
Employees
65000
CEO
Gilles Martin
WebsiteView website
www.eurofins.com

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services. In addition, it provides environment testing, including maritime, water, air, soil, building material, pollution, waste, fuel/oil, microplastics, and radioactivity testing; and food and feed testing that include allergen, audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, GMO, heavy metal, melamine, microbiology, molecular biology, mycotoxin, nutritional analyses, organic contaminants, pesticide, veterinary drug, vitamin, and residual DNA testing. Further, the company provides forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services, as well as in vitro diagnostics and PSS insourcing solutions. The company was founded in 1987 and is headquartered in Luxembourg, Luxembourg.

Recent ERF News & Updates

User avatar
Narrative Update • Aug 04

ERF: Acquisition Plans And Buybacks Will Support Balanced Long Term Outlook

The analyst price target for Eurofins Scientific has moved to €68.50 from €67.50, as analysts cite updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E to support their view. What's in the News Eurofins Scientific agreed to acquire Element Materials Technology’s Life Sciences Testing Services business in North America, with closing targeted for the fourth quarter of 2026 subject to customary regulatory approvals, according to recent company announcements.

Recent updates

No updates

Eurofins Scientific SE Competitors

SAN logo

Sanofi

Symbol: ENXTPA:SAN
Market cap: €88.7b
DIM logo

Sartorius Stedim Biotech

Symbol: ENXTPA:DIM
Market cap: €19.3b
IPN logo

Ipsen

Symbol: ENXTPA:IPN
Market cap: €12.8b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide